Allergic contact photodermatitis to para-aminobenzoic acid.

Allergic contact photodermatitis to para-aminobenzoic acid. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Allergic contact photodermatitis to para-aminobenzoic acid. Abstract Text:

Allergic photocontact dermatitis developed in a patient to a commercial sunscreen preparation containing para-aminobenzoic acid (PABA) in an alcohol base. Photopatch testing showed photosensitivity to PABA. Sensitization could only be detected when PABA was tested in an alcohol vehicle; a photopatch test to PABA in petrolatum was negative.

Allergic contact photodermatitis to para-aminobenzoic acid. Publishing Authors By Initials

For similar skin and connective tissue diseases: skin diseases: photosensitivity disorders research abstracts see: skin and connective tissue diseases: skin diseases: photosensitivity disorders research

PUBMED ID PMID:

MEDLINE DATE:

Allergic contact photodermatitis to para-aminobenzoic acid. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of dermatology

VOLUME: 114

Page Numbers: 1665-6

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Nov

YEAR: 1978

Allergic contact photodermatitis to para-aminobenzoic acid. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Allergic contact photodermatitis to para-aminobenzoic acid. Keywords Mesh Terms:

KEYWORDS: Photosensitivity Disorders

MESH TERMS: chemically induced

Chemical & Substance for Abstract: Allergic contact photodermatitis to para-aminobenzoic acid. Information

Substance Name: 4-Aminobenzoic Acid

Registry Number: 150-13-0

Grant and Affiliation Information for Allergic contact photodermatitis to para-aminobenzoic acid.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Allergic contact photodermatitis to para-aminobenzoic acid Related Publications

• A pharmacy benefit manager perspective.
• Analgesic and Antiinflammatory Activity of Antibodies to Histamine under Experimental Conditions.
• Antibodies to delta sleep-inducing Peptide in ultralow doses: study of the effect by enzyme immunoassay.
• Antiulcer Activity of Ultralow Doses of Antibodies to Histamine under Experimental Conditions.
• Changes in Immunological Parameters in Patients with Opium Abuse Receiving ANAR Therapy.
• Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.
• Co-twin control designs for testing behavioral economic theories of child nutrition: methodological note.
• Coexistence, competition and hypercyclic interaction in some systems of biological interest.
• Effect of Potentiated Antibodies to Cyclophosphamide on the Development of Tumors and Effectiveness of Cytostatic Therapy under Experimental Conditions.
• Effect of Potentiated Solutions on Mercury(II) Signal in Inversion Voltammetry.
• Effect of Preparations from Potentiated Ethanol on the Content of Biogenic Monoamines and Metabolism of Ethanol in Tissues of Rats during Alcoholization.
• Effect of allotransplantation of embryonic brain tissues and administration of potentiated antibodies to bombesin on hemodynamics in rats with emotional hypertension.
• Effect of antibodies to morphine in ultralow doses on induction of long-term potentiation in hippocampal slices from rats with chronic morphine dependence.
• Effect of potentiated antibodies to morphine on behavioral reactions in rats with morphine dependence.
• Effects of Potentiated Antibodies Against Brain-Specific S100 Protein on Biogenic Amine Content and Lipid Peroxidation in Rats under Conditions of Alcoholization.
• Effects of ultralow doses of antibodies to prostate-specific antigen on morphological and functional state of rat prostate.
• Efficiency of ultralow doses of antibodies to s100 protein and delta sleep-inducing Peptide in rats with anxious depression.
• Impaza and sildenafil: comparison of clinical effectiveness in patients with erectile dysfunction.
• Membranotropic effects of antibodies to s100 protein in ultralow doses.
• Metallothionein and catalase sensitize to diabetes in nonobese diabetic mice: reactive oxygen species may have a protective role in pancreatic beta-cells.
• Potentiated Antibodies to Tumor Necrosis Factor-alpha in the Therapy of Patients with Rheumatoid Arthritis.
• Potentiated antibodies against morphine: effects on biogenic amines and lipid peroxidation in chronically morphinized rats.
• Potentiated cyclophosphane: experimental study of the effect on tumor development and efficiency of cytostatic therapy.
• Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.
• Regulatory activity of ultralow doses.
• Relationship between sex of parent and child on weight loss and maintenance in a family-based obesity treatment program.
• Reperfused myocardial infarction in mice: 3D mapping of late gadolinium enhancement and strain.
• The challenge of Down syndrome.
• Ultralow Doses of Anti-Idiotypic Antibodies to Human gamma-Interferon: Immunotropic Properties.
• Use of potentiated preparations to relieve alcohol and opium withdrawal syndromes.